Suzhou Zelgen Biopharmaceuticals' (SHA:688266) net loss attributable to shareholders in 2024 narrowed to 137.8 million yuan or 0.52 yuan per share from 278.6 million yuan or 1.09 yuan per share in the previous year, according to a Shanghai Stock Exchange disclosure on Saturday.
The Chinese biopharmaceutical company's operating income jumped 38% to almost 533 million yuan from 386.4 million yuan a year earlier, the disclosure said.
The company's shares jumped less than 5% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments